Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells $12,133.21 in Stock

Posted by Stanley Muller on May 14th, 2026

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT – Get Free Report) General Counsel Martin Wilson sold 3,361 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $3.61, for a total value of $12,133.21. Following the transaction, the general counsel directly owned 678,639 shares in the company, valued at approximately $2,449,886.79. The trade was a 0.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Martin Wilson also recently made the following trade(s):

On Friday, February 13th, Martin Wilson sold 12,253 shares of Rocket Pharmaceuticals stock. The stock was sold at an average price of $3.31, for a total value of $40,557.43.

Rocket Pharmaceuticals Stock Performance

Shares of RCKT traded down $0.20 during mid-day trading on Thursday, hitting $3.40. 2,047,459 shares of the company’s stock were exchanged, compared to its average volume of 2,978,303. Rocket Pharmaceuticals, Inc. has a fifty-two week low of $2.19 and a fifty-two week high of $7.14. The firm has a market capitalization of $371.26 million, a P/E ratio of -1.82 and a beta of 0.52. The business’s 50 day moving average is $4.00 and its two-hundred day moving average is $3.68. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.08.

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.01). During the same period last year, the business posted ($0.56) EPS. On average, equities analysts expect that Rocket Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on RCKT shares. Cantor Fitzgerald increased their target price on shares of Rocket Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th. Chardan Capital reiterated a “buy” rating and set a $11.00 target price on shares of Rocket Pharmaceuticals in a research note on Monday. Lifesci Capital upgraded shares of Rocket Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, February 26th. Wall Street Zen downgraded shares of Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, March 8th. Finally, Weiss Ratings upgraded shares of Rocket Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Rocket Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $11.54.

View Our Latest Stock Analysis on Rocket Pharmaceuticals

Institutional Investors Weigh In On Rocket Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Federated Hermes Inc. lifted its position in Rocket Pharmaceuticals by 0.5% in the third quarter. Federated Hermes Inc. now owns 627,567 shares of the biotechnology company’s stock valued at $2,046,000 after purchasing an additional 3,264 shares during the period. Barclays PLC lifted its position in Rocket Pharmaceuticals by 2.4% in the fourth quarter. Barclays PLC now owns 153,049 shares of the biotechnology company’s stock valued at $537,000 after purchasing an additional 3,656 shares during the period. Hennion & Walsh Asset Management Inc. lifted its position in Rocket Pharmaceuticals by 1.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 309,247 shares of the biotechnology company’s stock valued at $1,085,000 after purchasing an additional 3,809 shares during the period. CANADA LIFE ASSURANCE Co lifted its position in Rocket Pharmaceuticals by 94.4% in the second quarter. CANADA LIFE ASSURANCE Co now owns 12,202 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 5,926 shares during the period. Finally, Sanctuary Advisors LLC lifted its position in Rocket Pharmaceuticals by 63.5% in the fourth quarter. Sanctuary Advisors LLC now owns 17,437 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 6,769 shares during the period. Institutional investors and hedge funds own 98.39% of the company’s stock.

About Rocket Pharmaceuticals

(Get Free Report)

Rocket Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing gene therapies for rare, inherited pediatric diseases. The company employs a proprietary adeno-associated virus (AAV) and lentiviral vector platform to deliver functional copies of genes in patients with genetic deficiencies. Its programs target a spectrum of disorders, including Fanconi anemia, leukocyte adhesion deficiency type I and Danon disease, with the goal of delivering one-time treatments that address the underlying causes of disease rather than merely managing symptoms.

The company’s pipeline comprises multiple product candidates in various stages of development.